Cont.:
2. From the FDA boss, mr McClellan:
“…. one key part of the FDA’s new medical innovation initiative is to try to facilitate the development of better treatments for obesity and diabetes. These are areas where we think regulatory pathways could be improved or better defined, and where we intend to give priority attention to potentially valuable new products.
3. Favourable toxicity draft reports.
Draft reports on 3 month toxicity studies in monkeys and rats have been received and are favourable.
Web site: http://www.metabolic.com.au/
If has a F&Q session. Suggest you read it. A reference is made to the obesity drug AOD9604 and publications.
2 OTHER DRUGS:
Investor update, date 18/10/2002:
http://stocknessmonster.com/news-item?S=MBP&E=ASX&N=196386
Extract: ADD9918/ADD9922 FOR TYPE II DIABETES
"ADD9918 and ADD9922 are analogs of fragments of insulin that cause potent insulin sensitization in animal models of type 2 diabetes.
They have the potential to provide a new treatment for type 2 diabetes. THere have been some problems with consistency of batches and the process has slowed down.
MBP0250 and MBP0260 FOR OSTEOPOROSIS
MBP0250 and MBP0260 are fragments of the hormones amylin and adrenomedullin with potential for the treatment of osteoporosis.
These compounds were exclusively licensed from the University of Auckland in March this year.
MBP0201 FOR IRON OVERLOAD
MBP0201 is a new compound with potential to provide an effective oral drug for iron overload diseases. This invention was exclusively licensed from Sydney's Heart Research Institute in March this year".
_________________________________
Summary: It is clear that most of the emphasis is placed on the obese drug AOD9604 at present. This drug could become important if it passes the trials. Sofar the results have been encouraging.
It is possible that if the results from Phase IIb trial of this obesity drug are positive (the trial only lasts 3 months, so we'll soon know), the FDA may step in and shorten the time to market: in my previous post, I already made reference to the FDA's interest in obesity.
It is pleasing therefore that MBP is in close contact with the FDA.
Gerry Stolwyk
Holds MBP.
Please do your own research and you decide if and when to buy, hold or sell any stocks.
- Forums
- ASX - By Stock
- MBP
- + + data and comment + +
+ + data and comment + +, page-2
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne